Compare Gilead Sciences, Inc. (GILD) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vital Farms Inc — how do they compare? Gilead Sciences, Inc. trades at $132.93 (market cap $163.51B), while Vital Farms Inc trades at $13.49 (market cap $581.88M). The key difference: Gilead Sciences, Inc. is far larger — about 281× Vital Farms Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| GILD | VITL | |
|---|---|---|
Market Cap | $163.51B | $581.88M |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $52.41 |
52-Week Low | $108.22 | $8.28 |
Enterprise Value | $178.05B | $584.69M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Vital Farms (VITL) trades at $13.54, up 3.28% with a bullish technical signal from moving averages and oscillators. The company shows solid fundamentals with a P/E of 13.06, P/S of 0.79, and strong profitability margins (ROE 15.44%, net margin 6.1%). Recent earnings have been mixed with Q3 2025 beating expectations but Q1 2026 missing, while analyst consensus remains positive with 56% buy ratings and a $13.50 price target.
The outlook suggests potential upside to the $16 high target given reasonable valuation and profitability, but risks include ongoing class action lawsuits, negative cash flow trends, and earnings volatility. Revenue growth is projected to slow from 2025 to 2026 with profit margins compressing from 8.72% to 6.1%, indicating execution challenges ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
